BioMimetic Therapeutics Inc. (BMTI) President and CEO Samuel Eugene Lynch sells 7,500 Shares

President and CEO of BioMimetic Therapeutics Inc. (BMTI, Financial) Samuel Eugene Lynch sells 7,500 shares of BMTI on 10/06/2009 at an average price of $12.14 a share.

Biomimetic Therapeutics Inc. has a market cap of $284.5 million; its shares were traded at around $13.08 with and P/S ratio of 90.4.

Recent Trades of BioMimetic Therapeutics Inc. by CEO:
  • Sell: President and CEO Samuel Eugene Lynch sold 9,000 shares of BMTI stock on 09/24/2009 at the average price of $13.03; the price of the stock has increased by 0.38% since.

  • Sell: President and CEO Samuel Eugene Lynch sold 6,000 more shares of BMTI stock on 09/10/2009 at the average price of $12; the price of the stock has increased by 9% since.

  • Sell: President and CEO Samuel Eugene Lynch sold 6,000 more shares of BMTI stock on 08/26/2009 at the average price of $11.59; the price of the stock has increased by 12.86% since.

  • Sell: President and CEO Samuel Eugene Lynch sold 6,000 more shares of BMTI stock on 08/13/2009 at the average price of $10.82; the price of the stock has increased by 20.89% since.

  • Sell: President and CEO Samuel Eugene Lynch sold 3,000 more shares of BMTI stock on 07/30/2009 at the average price of $10.09; the price of the stock has increased by 29.63% since.



Recent Trades of BioMimetic Therapeutics Inc. by Directors and Officers:
  • Buy: Director James G Murphy bought 508 shares of BMTI stock on 06/25/2009 at the average price of $8.5; the price of the stock has increased by 53.88% since.

  • Buy: 10% Owner A/s Novo bought 343,406 shares of BMTI stock on 06/25/2009 at the average price of $8.5; the price of the stock has increased by 53.88% since.

  • Buy: Director Gary E Friedlaender bought 8,174 shares of BMTI stock on 06/25/2009 at the average price of $8.5; the price of the stock has increased by 53.88% since.